A phase I/II study of CYC065 in combination with venetoclax for patients with relapsed or refractory chronic lymphocytic leukemia
Phase of Trial: Phase I
Latest Information Update: 28 Mar 2018
At a glance
- Drugs CYC 065 (Primary) ; Venetoclax (Primary)
- Indications Chronic lymphocytic leukaemia
- Focus Adverse reactions; Therapeutic Use
- 28 Mar 2018 According to a Cyclacel Pharmaceuticals media release, the protocol has been submitted to the US Food and Drug Administration or FDA.
- 09 Jan 2018 According to a Cyclacel Pharmaceuticals media release, company is planning to initiate this trial in 2018.
- 16 Nov 2017 Phase was mentioned as I/II based on MR 9221117. I have changed phase to Ib based on the recent MR 9226634.